Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease
- 20 May 2020
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 226, 188-197
- https://doi.org/10.1016/j.ahj.2020.05.011
Abstract
No abstract availableFunding Information
- National Centers for Advancing Translational Sciences (U01TR-001803-01, U24TR-001608-03)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U18FD-006298-02)
- National Centers for Advancing Translational Sciences (U01TR-001803-01, U24TR-001608-03)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U18FD-006298-02)
This publication has 33 references indexed in Scilit:
- Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think TankJournal of the American Heart Association, 2018
- The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2017 Update on Outcomes and QualityThe Annals of Thoracic Surgery, 2017
- Report of the 2015 Society of Thoracic Surgeons Congenital Heart Surgery Practice SurveyThe Annals of Thoracic Surgery, 2016
- The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studiesTrials, 2014
- Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.govAmerican Heart Journal, 2014
- The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?The New England Journal of Medicine, 2013
- A Global Rank End Point for Clinical Trials in Acute Heart FailureCirculation: Heart Failure, 2010
- Off-Label Use of Cardiovascular Medications in Children Hospitalized With Congenital and Acquired Heart DiseaseCirculation: Cardiovascular Quality and Outcomes, 2008
- A Global Ranking Approach to End Points in Trials of Mechanical Circulatory Support DevicesJournal of Cardiac Failure, 2008
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000